

**Dutasteride (Avodart<sup>®</sup>)**

**(No. 37/03)**

---

**GlaxoSmithKline**  
**Summary of Recommendation**

9 May 2003

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The recommendation is summarised as follows:

**ADVICE**

Recommended for general use within NHS Scotland.

**RECOMMENDATION**

Dutasteride has demonstrated similar efficacy and safety to alternative 5a-reductase inhibitors in reducing prostate volume in patients with BPH. Dutasteride is likely to be cost-neutral to NHS Scotland in the treatment of BPH.

Professor David H Lawson  
Chairman